Nevertheless, because of their ectopic or deregulated overexpression in up to 70% of all tumours, CEACAM5 and CEACAM6 represent popular targets for novel cancer therapies, including cancer vaccines, cellular immunotherapy, radioimmunotherapy, and antibody therapy. This evidence concerns the gene CEACAM5 and neoplasm.